Biomarkers, Imaging, and Safety in a Well-compensated NASH Cirrhotic Cohort Treated With Resmetirom, a Thyroid Hormone Receptor-beta Selective Agonist, for 52 Weeks - Schattenberg, Jörn; Kowdley, KrisV.; Taub, Rebecca A.; Alkhouri, Naim; Neff, Guy W.; Harrison, Stephen A. (Zeitschrift für Gastroenterologie, 2023)